Quest Diagnostics Inc
DGX
ISIN null / Valor 566162
Quest Diagnostics Inc
UMushroom community rating:
About company
Quest Diagnostics Inc. is a leading provider of diagnostic testing, information, and services, operating under the Quest® brand. The company and its affiliated CLIA certified laboratories offer a wide range of healthcare services, including diagnostic testing and information for patients and healthcare providers. Quest Diagnostics Inc. is known for its commitment to quality and accuracy in delivering results that help improve patient care and outcomes. Additionally, the company's services extend beyond traditional laboratory testing to include innovative solutions that support healthcare organizations in managing population health and improving overall patient wellness.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (09.09.2025):
Quest Diagnostics Inc reported robust financial performance for the second quarter of 2025, showcasing significant growth in revenues, earnings per share, and cash flow from operations. The company also provided an optimistic outlook for the full year, reflecting continued strategic execution and operational efficiencies.
Strong Revenue Growth
In the second quarter of 2025, Quest Diagnostics Inc achieved net revenues of $2.76 billion, marking a 15.2% increase compared to the same period in 2024. This growth includes a 5.2% contribution from organic revenues, driven by rising demand for clinical solutions and expanded enterprise business.
Increased Earnings Per Share
The company reported a diluted earnings per share (EPS) of $2.47 for the second quarter of 2025, representing a 21.7% rise from 2024. Additionally, the adjusted diluted EPS was $2.62, up by 11.5% year-over-year, highlighting improved profitability.
Substantial Cash Flow Increase
Year-to-date cash provided by operations reached $858 million in 2025, a significant 67.1% increase from 2024. This surge underscores Quest Diagnostics' strong operational performance and effective cash management strategies.
Raised Full-Year 2025 Guidance
Based on the impressive second-quarter results and ongoing positive trends, Quest Diagnostics Inc has updated its full-year 2025 guidance. The reported diluted EPS is now expected to range between $8.60 and $8.80, while the adjusted diluted EPS is projected to be between $9.63 and $9.83.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
21192 M
Market cap (USD)
983,924
Daily traded volume (Shares)
151.83 / 150.565
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
